Literature DB >> 28976226

Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.

Lorenzo Fornaro1, Valentina Fanotto2, Gianna Musettini1, Mario Uccello3, Lorenza Rimassa4, Caterina Vivaldi1, Caterina Fontanella2, Francesco Leone5, Riccardo Giampieri6, Gerardo Rosati7, Monica Lencioni1, Daniele Santini8, Samantha Di Donato9, Gianluca Tomasello10, Oronzo Brunetti11, Filippo Pietrantonio12, Francesca Bergamo13, Mario Scartozzi14, Antonio Avallone15, Stefania Eufemia Lutrino16, Davide Melisi17, Lorenzo Antonuzzo18, Antonio Pellegrino19, Lorenzo Gerratana2, Stefano Cordio3, Enrico Vasile1, Giuseppe Aprile2,20.   

Abstract

AIM: To evaluate the impact on overall survival (OS) of gastrectomy in asymptomatic metastatic esophago-gastric cancer. PATIENTS &
METHODS: Five hundred and thirteen patients were included. The role of surgery and other clinico-pathological factors was evaluated by univariate and Cox regression analyses. OS was the primary end point.
RESULTS: Multivariate analysis confirmed that gastrectomy was a predictor of longer OS (p < 0.001), as well as preserved performance status and benefit from first-line chemotherapy. None of the investigated clinico-pathological variables identified preferable candidates for surgery (all p > 0.05).
CONCLUSION: Palliative gastrectomy might play a role in asymptomatic metastatic esophago-gastric cancer patients with good performance status who received benefit from first-line chemotherapy. Future prospective trials integrating tumor biology among inclusion criteria may help defining the optimal candidates.

Entities:  

Keywords:  chemotherapy; metastatic gastric cancer; palliative gastrectomy

Mesh:

Year:  2017        PMID: 28976226     DOI: 10.2217/fon-2017-0246

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  6 in total

1.  SURGICAL TREATMENT IN CLINICAL STAGE IV GASTRIC CANCER: A COMPARISON OF DIFFERENT PROCEDURES AND SURVIVAL OUTCOMES.

Authors:  Marcus Fernando Kodama Pertille Ramos; Marina Alessandra Pereira; André Roncon Dias; Tiago Biachi de Castria; Erica Sakamoto; Ulysses Ribeiro-Jr; Bruno Zilberstein; Sérgio Carlos Nahas
Journal:  Arq Bras Cir Dig       Date:  2022-06-17

2.  A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial.

Authors:  Valeria Merz; Camilla Zecchetto; Francesca Simionato; Alessandro Cavaliere; Simona Casalino; Michele Pavarana; Simone Giacopuzzi; Maria Bencivenga; Anna Tomezzoli; Raffaela Santoro; Vita Fedele; Serena Contarelli; Irene Rossi; Serena Giacomazzi; Martina Pasquato; Cristiana Piazzola; Stefano Milleri; Giovanni de Manzoni; Davide Melisi
Journal:  Ther Adv Med Oncol       Date:  2020-07-07       Impact factor: 8.168

3.  An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer.

Authors:  Riccardo Giampieri; Luca Cantini; Michela Del Prete; Alessandro Bittoni; Enrica Giglio; Alessandra Mandolesi; Elena Maccaroni; Andrea Lanese; Tania Meletani; Maria Giuditta Baleani; Renato Bisonni; Marina Scarpelli; Rossana Berardi
Journal:  Oncol Lett       Date:  2021-02-09       Impact factor: 2.967

4.  Peri-operative Outcomes and Survival Following Palliative Gastrectomy for Gastric Cancer: a Systematic Review and Meta-analysis.

Authors:  Joseph Cowling; Bethany Gorman; Afrah Riaz; James R Bundred; Sivesh K Kamarajah; Richard P T Evans; Pritam Singh; Ewen A Griffiths
Journal:  J Gastrointest Cancer       Date:  2020-09-22

5.  Clinical characteristics and prediction model of long time survival of patients with stage M1 Siewert type II esophagogastric junction adenocarcinoma.

Authors:  Jun Zhang; Deruo Liu
Journal:  Transl Cancer Res       Date:  2021-05       Impact factor: 1.241

6.  Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma.

Authors:  Yuan Tian; Qun Zhao; Yong Li; Liqiao Fan; Zhidong Zhang; Xuefeng Zhao; Bibo Tan; Dong Wang; Peigang Yang
Journal:  Gastroenterol Res Pract       Date:  2021-07-22       Impact factor: 2.260

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.